---
title: "Insights into DexCom Q4 Earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275807215.md"
description: "DexCom (NASDAQ:DXCM) reported Q4 earnings on February 12, 2026, beating estimates by 4.62% with an EPS of $0.68 against an expected $0.65. Revenue increased by $146 million compared to the previous year. In the last quarter, DexCom also exceeded EPS estimates but experienced a 14.63% drop in share price the following day. Historical performance shows consistent revenue growth, with actual revenues surpassing estimates in recent quarters."
datetime: "2026-02-12T21:06:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275807215.md)
  - [en](https://longbridge.com/en/news/275807215.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275807215.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275807215.md) | [繁體中文](https://longbridge.com/zh-HK/news/275807215.md)


# Insights into DexCom Q4 Earnings

The earnings results for **DexCom** (NASDAQ:DXCM) for Q4 were made public on Thursday, February 12, 2026 at 04:03 PM.

Here's a comprehensive overview of the announcement.

### Earnings

DexCom beat estimated earnings by 4.62%, reporting an EPS of $0.68 versus an estimate of $0.65.

Revenue was up $146.00 million from the same period last year.

### Previous Earnings Records

Last quarter the company beat on EPS by $0.04 which was followed by a 14.63% drop in the share price the next day.

Here's a look at DexCom's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

0.57

0.45

0.33

0.50

**EPS Actual**

0.61

0.48

0.32

0.45

**Revenue Estimate**

1.18B

1.12B

1.02B

1.10B

**Revenue Actual**

1.21B

1.16B

1.04B

1.11B

To track all earnings releases for DexCom visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [DexCom, Inc. (DXCM.US)](https://longbridge.com/en/quote/DXCM.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/en/news/281179756.md)
- [Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06](https://longbridge.com/en/news/280788653.md)
- [Canaccord Genuity Group Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $5.00](https://longbridge.com/en/news/281425457.md)
- [RBC Capital Reaffirms Their Buy Rating on Insulet (PODD)](https://longbridge.com/en/news/281669086.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md)